Stockreport

New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States

Definium Therapeutics, Inc. - Common Shares  (DFTX) 
PDF The annual prevalence of newly diagnosed generalized anxiety disorder (GAD) increased from 5.4% in 2020 to 6.6% in 2023The 3-year total prevalence of GAD reached 10.3%, [Read more]